You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽-B(2256.HK)今日港交所首日交易 主打小分子腫瘤藥物
格隆匯 10-15 10:44
格隆匯10月15日丨由於颱風及重陽節休市,原本週三掛牌上市的和譽-B(2256.HK)今日在港交所首日交易。該股IPO以上限12.46港元定價,市值87億港元。和譽生物專注研發小分子藥物,尤其是聚焦於以小分子免疫腫瘤領域和亞洲人羣高發癌症,開發新穎和高潛力的藥物靶點的first in class或best in class。目前,公司主要就治療肝細胞癌(HCC)、尿路上皮癌(UC)及胃癌(GC)開發核心候選產品。恆瑞醫藥孫飄揚、上海微創醫療機器人孫洪斌、阿斯利康王磊擔任該公司獨立董事。另外值得一提的是,今年9月,和譽醫藥開發的創新小分子PD-L1抑制劑ABSK043的I期臨牀試驗已於澳大利亞完成首例患者給藥,旨在評估其治療實體瘤的安全性、耐受性、藥代動力學及初步抗腫瘤療效。和譽此次公開發行的基石投資者包括LAV, UBS, BlackRock, Warburg Pincus, Temasek, OrbiMed, Vivo, Hudson Bay, Lake Bleu Prime, Janchor Partners, AIHC。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account